Teysuno (gimeracil/oteracil/tegafur)

The patient underwent chemoradiotherapy consisting of 60 Gy in 30 fractions combined with gemcitabine+nab-paclitaxel...Histopathological evaluation revealed no viable cancer cells, showing only post-treatment changes, consistent with a pathological complete response(Grade 4). The postoperative course was uneventful, and at 6 months post-adrenalectomy, the patient remains recurrence-free without further adjuvant therapy.

Because of HER2 negative, 2 courses of ramucirumab plus paclitaxel was administered, but lung metastasis, increased liver metastasis, and ascites were detected...Nivolumab treatment was continued, and there has been no further disease progression at 83 months post-surgery. This case shows that disease control was achieved with nivolumab for liver, lung, and lymph node metastases following gastric cancer surgery, and long-term survival was attained with multimodal therapy.

We experienced a case of pCR induced by GCS chemotherapy and pembrolizumab monotherapy. Although the direct contribution of pembrolizumab remains unclear, a possible synergistic effect with GCS chemotherapy was suggested, particularly in MSI-H tumors.

Clinicians need to recognize that PACP can metastasize to the heart and incorporate this risk into routine follow-up, maintaining vigilance for imaging features suggestive of cardiac involvement and for new-onset cardiac symptoms or conduction disturbances; when cardiac metastasis is suspected, prompt evaluation and intervention are warranted.

P1/2, N=84, Recruiting, West China Hospital | Enrolling by invitation --> Recruiting

P2, N=40, Recruiting, Ruijin Hospital | Trial completion date: Jun 2026 --> Dec 2026

Our study suggests that the lack of NAC response to DS/DCS therapy is associated with increased tumor proliferation, a poor antitumor immune response, and the reduced expression of these five genes (ZNF296, RASSF10, EXOC3L1, KIAA0895 and GALNTL1). These genes represent promising candidates for further investigation as biomarkers for predicting treatment efficacy and as novel therapeutic targets.

P2, N=30, Not yet recruiting, Hebei Medical University

The DFS advantage was consistent across prespecified subgroups, particularly in patients aged ≥65 years, those with cT2-3 or cN0-1 disease, and proximal tumors. These findings indicate that neoadjuvant DOS induces deeper pathological regression and longer DFS than SOX without compromising surgical safety, supporting taxane-based triplets as a preferred perioperative option for HER2-negative LAGC; longer follow-up will clarify any impact on OS.

GS was superior to S-1 in CA19-9-positive patients. The correlation between genetic mutation profiles and adjuvant treatment outcomes in pancreatic cancer requires further exploration.

P2, N=116, Recruiting, Xijing Hospital | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Mar 2026

P3, N=738, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed